Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
AssigneeImmatics Biotechnologies GmbH
InventorJörn Dengjel
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Claims9
An isolated tumour associated peptide consisting of the peptide set forth in SEQ ID NO:35 flanked by N- and/or C-terminal extensions from 1 to 10 amino acids in length.
A fusion protein comprising a peptide set forth in SEQ ID NO:
- 35, and N-terminal amino acids of HLA-DR antigen-associated invariant chain (Ii). the method comprising:
- culturing a host cell in a culture medium, wherein the host cell is a recombinant RCC or Awelss cell;
- and isolating the peptide from the host cell or its culture medium.
An isolated tumour associated peptide consisting of the peptide set forth in SEQ ID NO:35.
Dependencies are inferred from the claim text.